Source comparison
Tesamorelin Interactions: Clinical Comparison
Corticosteroids (>7.5mg prednisone equivalent daily) Direct suppression of pituitary GH secretion; increased hypothalamic somatostatin release 40–60% reduction in tesamorelin-stimulated GH pulse; blunted IGF-1 response IGF-1 at baseline, week 4, week 8, then e
This comparison does not assign a generated winner or score.
- Corticosteroids (>7.5mg prednisone equivalent daily)
- Direct suppression of pituitary GH secretion; increased hypothalamic somatostatin release
- 40–60% reduction in tesamorelin-stimulated GH pulse; blunted IGF-1 response
- IGF-1 at baseline, week 4, week 8, then every 6 weeks
- Separate dosing by 10–12 hours; consider 20–30% tesamorelin dose increase if IGF-1 remains subtherapeutic
- High-dose corticosteroids significantly impair tesamorelin efficacy. Alternative visceral fat interventions may be more appropriate
- Insulin and Insulin Secretagogues
- GH-induced insulin resistance via increased lipolysis and hepatic gluconeogenesis
- 10–20% increase in insulin requirements; fasting glucose elevation of 8–15 mg/dL
- Fasting glucose at baseline, weeks 4 and 12, quarterly; HbA1c quarterly; CGM first month if available
- Proactive insulin dose increases during weeks 2–4; metformin co-administration attenuates glucose effect
- Predictable interaction requiring dose adjustment but rarely prohibitive. Close monitoring prevents glycemic deterioration
- GLP-1 Receptor Agonists (semaglutide, tirzepatide, liraglutide)
- Opposing effects on insulin sensitivity; GLP-1 agonists counteract GH-induced hyperglycemia
- Glucose typically stable or improved; potential for excessive appetite suppression affecting protein intake
- Body composition analysis (DEXA preferred) at baseline and 12 weeks; fasting glucose quarterly
- Ensure protein intake ≥1.6 g/kg daily; monitor for lean mass preservation
- Favorable metabolic interaction but requires body composition tracking to prevent muscle loss from appetite suppression
- Levothyroxine (Thyroid Replacement)
- GH increases peripheral T4-to-T3 conversion; may unmask subclinical hypothyroidism or induce relative hyperthyroidism
- 12–18% of patients require levothyroxine dose reduction (average 12.5mcg); TSH suppression if dose not adjusted
- TSH and free T4 at baseline, week 8, week 16
- Reduce levothyroxine by 12.5mcg if TSH <0.4 mIU/L; recheck in 6 weeks
- Routine interaction easily managed with standard thyroid monitoring. Does not limit tesamorelin use
- CYP3A4 Substrates (immunosuppressants, certain statins, calcium channel blockers)
- GH-mediated upregulation of hepatic CYP3A4 may increase substrate clearance
- Potential 10–25% reduction in plasma concentrations of CYP3A4-dependent drugs
- Therapeutic drug monitoring (TDM) for narrow-therapeutic-index drugs at weeks 4 and 12
- TDM for tacrolimus, cyclosporine, sirolimus; clinical monitoring for statins and calcium channel blockers
- Significant only for drugs with narrow therapeutic windows. Most substrates tolerate minor concentration changes without clinical consequence
- Protease Inhibitors (ritonavir-boosted regimens)
- Dual effect: PIs cause lipodystrophy tesamorelin treats; PIs inhibit CYP3A4 which GH upregulates
- Net effect on CYP3A4 substrates unclear; lipodystrophy indication remains valid
- Baseline and 12-week lipid panel, fasting glucose, liver function tests
- Standard tesamorelin dosing; no specific adjustment for PI interaction
- Tesamorelin is FDA-approved specifically for PI-associated lipodystrophy. Interaction data support safety in this population